

Supplementary Table 4. Evaluation of steatosis using attenuation coefficient and controlled attenuation parameters in patients with BMI equal to or greater than 25 (n=47)

	≥S1 (≥5% steatosis)	≥S2 (≥34% steatosis)	≥S3 (≥67% steatosis)
Attenuation coefficient from ATI			
AUROC (95% CI)	0.92 (0.81–0.98)	0.88 (0.75–0.96)	0.87 (0.74–0.95)
Prevalence (n)	38	17	3
Cutoff (dB/cm/MHz)	0.62	0.69	0.78
Sensitivity	0.84 (32/38)	0.88 (15/17)	1.00 (3/3)
Specificity	1.00 (9/9)	0.73 (22/30)	0.80 (35/44)
PPV	1.00 (32/32)	0.65 (15/23)	0.25 (3/12)
NPV	0.60 (9/15)	0.92 (22/24)	1.00 (35/35)
Controlled attenuation parameter from TE			
AUROC (95% CI)	0.94 (0.82–0.99)	0.86 (0.73–0.94)	0.80 (0.66–0.90)
Prevalence (n)	38	17	3
Cutoff (dB/m)	240	285	294
Sensitivity	0.92 (35/38)	0.88 (15/17)	1.00 (3/3)
Specificity	1.00 (9/9)	0.77 (23/30)	0.61 (27/44)
PPV	1.00 (35/35)	0.68 (15/22)	0.15 (3/20)
NPV	0.75 (9/12)	0.92 (23/25)	1.00 (27/27)

BMI, body mass index; ATI, attenuation imaging; AUROC, area under the receiver operating characteristic curve; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; TE, transient elastography.

Supplementary Table 5. Patient characteristics according to the stage of liver fibrosis

	F0 (n=63)	F1 (n=25)	F2 (n=5)	F3 (n=7)	F4 (n=5)
Age (year)	31.0 (25.0–38.0)	44.0 (27.8–51.5)	62.0 (47.5–66.5)	63.0 (53.3–66.8)	63.0 (57.8–69.8)
Sex (male:female)	32:31	12:13	2:3	5:2	2:3
Body mass index (kg/m ²)	23.3 (20.9–26.2)	25.4 (23.6–31.2)	25.2 (22.2–29.4)	26.9 (24.8–28.9)	27.3 (25.1–28.2)
Hypertension	14	6	2	4	5
Diabetes mellitus	0	7	4	5	4
ALT (IU/L)	14.0 (9.0–19.8)	75.0 (42.8–124.0)	32.0 (19.0–64.0)	73.0 (47.0–112.0)	28.0 (26.0–79.8)
AST (IU/L)	18.0 (15.0–21.8)	54.0 (26.0–96.0)	50.0 (26.3–85.0)	60.0 (52.3–65.5)	42.0 (27.3–56.5)
Albumin (mg/dL)	4.3 (4.1–4.5)	4.4 (4.0–4.6)	3.6 (2.7–3.7)	4.3 (4.1–4.5)	4.0 (3.6–4.2)
Total bilirubin (mg/dL)	0.6 (0.5–0.9)	0.6 (0.4–1.1)	0.8 (0.4–1.4)	0.6 (0.4–0.6)	0.5 (0.4–0.7)
PT-INR	1.02 (0.97–1.06)	1.01 (0.99–1.08)	1.12 (1.01–1.30)	0.98 (0.96–1.00)	1.01 (0.98–1.17)

Values are presented as median (IQR) or number (%).

IQR, interquartile range; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT-INR, prothrombin time international normalized ratio.